文献速递腹部技术与安全PETCT

[18F]FDG PET衍生参数对结直肠癌微卫星不稳定性及预后的预测价值

Predictive value of [18F]FDG PET-derived parameters for microsatellite instability and prognosis in patients with colorectal cancer.
PubMed 文献 · Eur Radiol · 2025-06-12

回顾性纳入两家医院182例结直肠癌患者,术前[18F]FDG PET/CT衍生参数用于预测微卫星不稳定性(MSI)状态及术后进展。MSI-H组SUVmax、MTV及IMH指数较高,较高MTV和IMH指数独立相关于MSI-H。PET参数可对MSS亚组进行预后分层,但在MSI-H组未能预测进展风险。

要点

  • MSI-H结直肠癌较MSS肿瘤表现出更高的[18F]FDG摄取和瘤内代谢异质性。
  • 较高MTV和IMH指数独立相关于MSI-H状态,可用于术前无创预测MSI。
  • PET衍生参数可对MSS亚组进行进展风险分层,但在MSI-H组无统计学意义。

核心结论

  • PET衍生参数在预测结直肠癌患者MSI状态及对MSS亚组进行预后分层方面表现出有前景的性能,但无法预测MSI-H患者的进展风险。

研究设计与样本

  • 回顾性收集两家参与医院的[18F]FDG PET/CT及匹配的MSI状态资料,共纳入182例结直肠癌患者,计算SUV、MTV、TLG和IMH指数,按截断值二分类后行logistic回归和Cox比例风险模型分析。

关键影像表现/征象

  • MSI-H组与MSS组之间CEA水平、肿瘤分化、pTNM、SUVmax、MTV和IMH指数差异有统计学意义,且与MSI-H相关。
  • 较高MTV和IMH指数独立相关于MSI-H。
  • 整体队列和MSS亚组中多数临床病理特征及PET衍生参数对预测术后进展有统计学意义,但在MSI-H组无统计学意义。

诊断标准与关键数值

  • 182例结直肠癌患者中34例(18.7%)为MSI-H,48例(26.4%)检测到进展。
  • 肿瘤分化、黏液成分和IMH指数被确定为MSS亚组无进展生存的独立预测因素。
  • MSI-H组中仅差/中-差分化和进展相关,PET衍生参数均无统计学意义。

临床应用与阅片要点

  • 术前[18F]FDG PET衍生参数(MTV、IMH指数)可用于无创预测结直肠癌MSI状态。
  • PET衍生参数可用于MSS亚组患者的预后分层。
  • MSI-H肿瘤中[18F]FDG摄取程度可能不反映疾病进展风险,阅片时需结合MSI状态解读PET参数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate [18F]FDG PET-derived parameters for preoperative predictive value of microsatellite instability (MSI) status and clinical outcomes in colorectal cancer (CRC) patients.

MATERIALS AND METHODS: [18F]FDG PET/CT with matched MSI status were retrospectively collected from two participating hospitals. The standard uptake value (SUV), metabolic tumour volume (MTV), total lesion glycolysis (TLG) and intratumoural metabolic heterogeneity (IMH) index were calculated and compared between the microsatellite stability (MSS) and MSI high (MSI-H) groups. PET-derived parameters were dichotomized according to cut-off values, and regression analysis was conducted, including logistic regression and Cox proportional hazards modelling, to predict MSI status and postoperative progression, respectively.

RESULTS: Among 182 CRC patients, 34 (18.7%) exhibited MSI-H, and progression was detected in 48 (26.4%) patients. The difference in CEA levels, tumour differentiation, pTNM, SUVmax, MTV, and IMH index between the two groups was statistically significant and correlated with MSI-H. Higher MTV and IMH indices independently correlated with MSI-H. Meanwhile, most clinicopathologic characteristics and PET-derived parameters were significant for predicting postoperative progression in the overall cohort and MSS subgroup patients, but not in the MSI-H group. Tumour differentiation, mucinous component, and IMH index were identified as independent predictors of progression-free survival for the MSS subgroup. In contrast, only poor/moderate-poor differentiation was associated with progression in the MSI-H group, with none of the PET-derived parameters showing statistical significance.

CONCLUSION: The PET-derived parameters demonstrated promising performance in predicting MSI status in CRC patients and stratifying prognosis in the MSS subgroup. However, these parameters were unable to predict progression risk in MSI-H patients.

KEY POINTS: Question Can PET-derived parameters offer a safe and non-invasive method to predict microsatellite instability (MSI) status in colorectal cancer (CRC) patients and enhance prognostic stratification? Findings MSI-H CRC exhibited higher [18 F]FDG uptake and intratumoural metabolic heterogeneity compared with microsatellite stability (MSS) tumours, and PET-derived parameters can stratify the progression of CRC patients with MSS but not in MSI-H tumours. Clinical relevance Our study provides a non-invasive method based on PET-derived parameters to predict MSI status and enhance prognostic stratification of CRC patients with MSS, whereas the degree of [18 F]FDG uptake may not reflect the disease progression risk of MSI-H tumours.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Guo W, Jiang H, Wang C, et al. Predictive value of [18F]FDG PET-derived parameters for microsatellite instability and prognosis in patients with colorectal cancer. Eur Radiol. 2025. PMID: 40506639. doi:10.1007/s00330-025-11732-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。